We further divided our recruited LUAD patients into WT and MT EGFR groups and observed that IL-17A rs8193036 T allele carriers (CT or TT) with the WT EGFR had enhanced risks of developing advanced-stage tumors (stage III or IV; AOR: 4.175; 95% CI: 1.312~13.285, p = 0.016) and lymph node metastasis (AOR: 2.839; 95% CI: 1.005~8.018, p = 0.049) (Table 4). Here, EGFR is linked to metastatic malignant neoplasm in the lymph nodes.